Debanjana Chatterjee
Stock Analyst at Jones Trading
(2.74)
# 1,622
Out of 4,944 analysts
10
Total ratings
66.67%
Success rate
16.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $12.42 | +93.24% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $9.58 | +181.84% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $24.05 | +62.16% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $12.59 | +138.38% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $6.98 | +229.51% | 1 | Mar 13, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $17.40 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $21.43 | +114.65% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $11.00 | +272.73% | 1 | Sep 17, 2024 |
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $12.42
Upside: +93.24%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $9.58
Upside: +181.84%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $24.05
Upside: +62.16%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $12.59
Upside: +138.38%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $6.98
Upside: +229.51%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $17.40
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $21.43
Upside: +114.65%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $11.00
Upside: +272.73%